Prediction of drug absorption: Different modeling approaches from discovery to clinical development

Expert Review of Clinical Pharmacology

Volumn 2, Issue 3, 2009, Pages 217-219

  Kuentz, Martin ^a  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; EDITORIAL; MATHEMATICAL MODEL; PARTICLE SIZE; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 70149103354     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.2     Document Type: Editorial

References (27)

1. van de Waterbeemd H, Gifford E. ADMET in silico modeling: towards prediction paradise? Nat. Rev. Drug Disc. 2(3), 192-204 (2003).
2. Lipinski CA, Lombardo F, Dominy BW et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23(1-3), 3-25 (1997).
3. Perez MAC, Sanz MB, Torres LR, Avalos RG, Gonzalez MP, Diaz HG. A topological sub-structural approach for predicting human intestinal absorption of drugs. Eur. J. Med. Chem. 39(11), 905-916 (2004).
4. Deconinck E, Xu QS, Put R, Coomans D, Massart DL, Vander Heyden Y. Prediction of gastro-intestinal absorption using multivariate adaptive regression splines. J. Pharm. Biomed. Anal. 39(5), 1021-1030 (2005).
5. Deconinck E, Ates H, Callebaut N, Van Gyseghem E, Vander Heyden Y. Evaluation of chromatographic descriptors for the prediction of gastro-intestinal absorption of drugs. J. Chromatogr. A. 1138(1-2), 190-202 (2007).
6. Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J. Chem. Inf. Model. 47(1), 208-218 (2007).
7. Hou T, Wang J, Li Y. ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. J. Chem. Inf. Model. 47(6), 2408-2415 (2007).
8. Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound: development of a novel quantitative structure - bioavailability relationship. Pharm. Res. 17(6), 639-644 (2000).
9. Yoshida F, Topliss JG. QSAR model for drug human oral bioavailability. J. Med. Chem. 43(13), 2575-2585 (2000).
10. Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J. Chem. Inf. Model. 47(2), 460-463 (2007).
11. Kuentz M, Arnold Y. Influence of molecular properties on oral bioavailability of lipophilic drugs - mapping of bulkiness and polarity. Pharm. Dev. Technol. DOI: 10.1080/10837450802626296 (2009).
12. Yu L, Amidon G. Saturable small intestinal drug absorption in humans: Modeling and interpretation of cefatrizine data. Eur. J. Pharm. Biopharm. 45(2), 199-203 (1998).
13. Agoram B, Woltosz W, Bolger M. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50(S1), S41-S67 (2001).
14. Willmann S, Schmitt W, Keldenich J, Dressman J. A physiological model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res. 20(11), 1766-1771 (2003).
15. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman J. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47(16), 4022-4031 (2004).
16. Willmann S, Ediginton AN, Dressman J. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm. Res. 24(7), 1275-1282 (2007).
17. Dannenfelser RM, He H, Joshi Y, Bateman S, Serajuddin A. Development of clinical dosage forms for a poorly water soluble drug I: application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J. Pharm. Sci. 93(5), 1165-1175 (2004).
18. Kuentz M, Nick S, Parrott N, Roethlisberger D. A strategy for preclinical formulation development using GastroPlus™ as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci. 27(1), 91-99 (2006).
19. Dressman J, Amidon G, Reppas C, Shah V. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15, 11-22 (1998).
20. Vertzoni M, Fotaki N, Kostewicz E et al. Dissolution media simulation the intralumenal composition of the small intestinal intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 56, 453-562 (2004).
21. Wei H, Löbenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Euro. J. Pharm. Sci. 29, 45-52 (2006).
22. Jantratid E, Janssen N, Reppas C, Dressman J. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25(7), 1663-1676 (2008).
23. Kuentz M, Wyttenbach N, Kuhlmann O. Application of a statistical method to the absorption of a new model drug from micellar and lipid formulations - evaluation of qualitative excipient effects. Pharm. Dev. Technol. 12(3), 275-283 (2007).
24. Jantratid E, Janssen N, Chokshi H, Tang K, Dressman J. Designing biorelevant dissolution tests for lipid formulations: case example - lipid suspension of RZ-50. Eur J. Pharm. Biopharm. 69, 776-785 (2008).
25. Sek L, Porter C, Kaukonen AM, Charman W. Evaluation of the in-vitro digestion profiles for long and medium chain triglycerides and the phase behaviour of the lipolytic products. J. Pharm. Pharmacol. 54, 29-41 (2002).
26. Fatouros DG, Müllertz A. In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability. Expert Opin. Drug Metab. Toxicol. 4(1), 65-76 (2008).
27. Kuentz M. Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J. 10(3), 473-479 (2008).